Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Bought by JPMorgan Chase & Co.

JPMorgan Chase & Co. raised its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 40.6% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 253,396 shares of the specialty pharmaceutical company's stock after acquiring an additional 73,118 shares during the period. JPMorgan Chase & Co. owned approximately 0.46% of Supernus Pharmaceuticals worth $7,901,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in SUPN. Commonwealth Equity Services LLC boosted its stake in Supernus Pharmaceuticals by 3.6% during the second quarter. Commonwealth Equity Services LLC now owns 10,195 shares of the specialty pharmaceutical company's stock worth $273,000 after buying an additional 350 shares during the last quarter. Texas Permanent School Fund Corp boosted its position in shares of Supernus Pharmaceuticals by 9.2% during the 2nd quarter. Texas Permanent School Fund Corp now owns 52,214 shares of the specialty pharmaceutical company's stock valued at $1,397,000 after acquiring an additional 4,400 shares during the last quarter. American Century Companies Inc. grew its holdings in shares of Supernus Pharmaceuticals by 369.1% in the second quarter. American Century Companies Inc. now owns 501,658 shares of the specialty pharmaceutical company's stock valued at $13,419,000 after purchasing an additional 394,728 shares during the period. Dimensional Fund Advisors LP grew its holdings in shares of Supernus Pharmaceuticals by 12.1% in the second quarter. Dimensional Fund Advisors LP now owns 2,866,887 shares of the specialty pharmaceutical company's stock valued at $76,690,000 after purchasing an additional 309,966 shares during the period. Finally, Renaissance Technologies LLC increased its position in Supernus Pharmaceuticals by 26.4% during the second quarter. Renaissance Technologies LLC now owns 1,685,122 shares of the specialty pharmaceutical company's stock worth $45,077,000 after purchasing an additional 351,900 shares during the last quarter.

Insider Buying and Selling

In other news, CEO Jack A. Khattar sold 125,000 shares of the business's stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $36.68, for a total transaction of $4,585,000.00. Following the completion of the transaction, the chief executive officer now directly owns 926,172 shares of the company's stock, valued at approximately $33,971,988.96. The trade was a 11.89 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Frank Mottola sold 15,000 shares of the business's stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $36.98, for a total transaction of $554,700.00. Following the transaction, the senior vice president now owns 8,200 shares of the company's stock, valued at approximately $303,236. The trade was a 64.66 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 154,213 shares of company stock valued at $5,660,180 in the last ninety days. Company insiders own 9.30% of the company's stock.

Analysts Set New Price Targets

SUPN has been the topic of several recent analyst reports. Cowen reiterated a "buy" rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th. Cantor Fitzgerald started coverage on Supernus Pharmaceuticals in a report on Monday, January 6th. They issued an "overweight" rating and a $57.00 price objective on the stock. Finally, Piper Sandler reissued a "neutral" rating on shares of Supernus Pharmaceuticals in a research note on Friday, October 18th.

Supernus Pharmaceuticals Stock Up 1.3 %

Shares of SUPN traded up $0.49 during trading on Wednesday, reaching $38.31. 333,195 shares of the company traded hands, compared to its average volume of 361,912. The stock has a 50-day simple moving average of $36.61 and a 200-day simple moving average of $33.51. The stock has a market cap of $2.12 billion, a PE ratio of 35.80 and a beta of 0.90. Supernus Pharmaceuticals, Inc. has a twelve month low of $25.53 and a twelve month high of $39.37.

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) last announced its earnings results on Monday, November 4th. The specialty pharmaceutical company reported $0.69 EPS for the quarter, beating analysts' consensus estimates of $0.44 by $0.25. The company had revenue of $175.70 million during the quarter, compared to analysts' expectations of $157.35 million. Supernus Pharmaceuticals had a return on equity of 7.79% and a net margin of 9.16%. Supernus Pharmaceuticals's revenue for the quarter was up 14.2% on a year-over-year basis. During the same period last year, the business posted ($0.29) EPS. On average, equities research analysts predict that Supernus Pharmaceuticals, Inc. will post 2.37 EPS for the current year.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.